GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tauns Laboratories Inc (TSE:197A) » Definitions » Asset Turnover

Tauns Laboratories (TSE:197A) Asset Turnover : 0.00 (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Tauns Laboratories Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Tauns Laboratories's Revenue for the three months ended in Dec. 2024 was 円0 Mil. Tauns Laboratories's Total Assets for the quarter that ended in Dec. 2024 was 円32,637 Mil. Therefore, Tauns Laboratories's Asset Turnover for the quarter that ended in Dec. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Tauns Laboratories's annualized ROE % for the quarter that ended in Dec. 2024 was 0.00%. It is also linked to ROA % through Du Pont Formula. Tauns Laboratories's annualized ROA % for the quarter that ended in Dec. 2024 was 0.00%.


Tauns Laboratories Asset Turnover Historical Data

The historical data trend for Tauns Laboratories's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tauns Laboratories Asset Turnover Chart

Tauns Laboratories Annual Data
Trend Jun22 Jun23 Jun24
Asset Turnover
0.86 0.81 0.78

Tauns Laboratories Quarterly Data
Jun22 Jun23 Mar24 Jun24 Dec24
Asset Turnover - - - 0.07 -

Competitive Comparison of Tauns Laboratories's Asset Turnover

For the Medical Instruments & Supplies subindustry, Tauns Laboratories's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tauns Laboratories's Asset Turnover Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tauns Laboratories's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Tauns Laboratories's Asset Turnover falls into.


;
;

Tauns Laboratories Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Tauns Laboratories's Asset Turnover for the fiscal year that ended in Jun. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Jun. 2024 )/( (Total Assets (A: Jun. 2023 )+Total Assets (A: Jun. 2024 ))/ count )
=18434.863/( (18332.162+29261.325)/ 2 )
=18434.863/23796.7435
=0.77

Tauns Laboratories's Asset Turnover for the quarter that ended in Dec. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=0/( (29261.325+36012.538)/ 2 )
=0/32636.9315
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Tauns Laboratories  (TSE:197A) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Tauns Laboratories's annulized ROE % for the quarter that ended in Dec. 2024 is

ROE %**(Q: Dec. 2024 )
=Net Income/Total Stockholders Equity
=0/14978.949
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(0 / 0)*(0 / 32636.9315)*(32636.9315/ 14978.949)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*2.1789
=ROA %*Equity Multiplier
=0.00 %*2.1789
=0.00 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Tauns Laboratories's annulized ROA % for the quarter that ended in Dec. 2024 is

ROA %(Q: Dec. 2024 )
=Net Income/Total Assets
=0/32636.9315
=(Net Income / Revenue)*(Revenue / Total Assets)
=(0 / 0)*(0 / 32636.9315)
=Net Margin %*Asset Turnover
= %*0
=0.00 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Tauns Laboratories Asset Turnover Related Terms

Thank you for viewing the detailed overview of Tauns Laboratories's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Tauns Laboratories Business Description

Traded in Other Exchanges
N/A
Address
761-1 Kamishima Izunokuni-shi, Shizuoka, JPN, 410-2325
Tauns Laboratories Inc is engaged in development, manufacture and sales of in vitro diagnostics and research reagents. Its product include Capilia Flu Neo, Capilia Adeno Neo, Capilia RSV Neo, Capilia hMPV, etc.

Tauns Laboratories Headlines

No Headlines